SimuGen is an international computational biology company focused on predicting human toxicity early on in drug discovery. The company combines traditional, genomic, high content (HCS) in vitro screening and traditional cell endpoints, to produce high throughput screens for use alongside other early ADME testing.
SimuGen offers comprehensive toxicology screening services (HT-X™) and high-throughput decision analytics software (HT-Stream™) for customers’ drug programmes. SimuGen's goal is to meet a major market gap that is not adequately addressed by current toxicogenomics - to accurately predict toxicity in the early stages of drug discovery.
The company was originally born in 2006 out of the talents of the Cambridge and Oxford technology clusters in the UK. In 2008 the company expanded into the Asia Pacific Region, with the establishment of premises in Kuala Lumpur (Malaysia). SimuGen also has an office in London (UK) to retain close relationships with Europe's leading bioscience and technology pools.